IMPAACT at AIDS 2018

Protocol

Title

Authors

Presentation Type

P1074/ CIPHER

Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a CIPHER cohort collaboration global analysis

Patel K, Smith C, Collins IJ, Goodall R, Abrams E, Sohn A, Mohamed T, Van Dyke R, Rojo P, Wools-Kaloustian K, Pinto J, Edmonds A, Marete I, Paul M, Nuwaqaba-Biribonwoha H, Leroy V, Davies M-A, Vreeman R, CIPHER Cohort Collaboration Duration of Second-line Proj

Oral presentation

P1076

Alendronate improves bone mineral density in perinatally HIV-infected children and adolescents

Jacobson D, Lindsay J, Spiegel H, Hazra R, Siberry G, for the IMPAACT P1076 Study Team

Oral presentation

PROMISE 1077BF

Role of maternal viral load and CD4 count on perinatal HIV-1 transmission during breastfeeding in the PROMISE postpartum component

Flynn P, Taha T, Cababasay M, Butler K, Fowler MG, Mofenson L, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanshanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga B, Masenya M, Nyati M, Theron G, Mulenga H, Shapiro D, and the PROMISE Study Team

Oral presentation

PROMISE 1077BF

Intracellular concentrations of tenofovir diphosphate (TFV-DP) during pregnancy in the PROMISE study: Description and relationship with adverse pregnancy outcomes

Aizire J, Brooks KM, Mirochnick M, Flynn P, Cababasay M, Kiser JJ, Siberry G, Fenton T, Butler K, Fowler MG, and the PROMISE Study Team

Poster presentation

P1104s

Caregiver depression and child neuropsychological outcomes in an observational study carried out in four Sub-Saharan countries

Familiar I, Chernoff M, Ruiseñor-Escudero H, Laughton B, Joyce C, Fairlie L, Bwakura-Dangarembizi M, Kamthunzi P, Barlow L, Jean-Philippe P, Zimmer B, McCarthy K, Boivin M

Oral presentation

P1110

IMPAACT P1110: Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: Dose-finding study in infants born to mothers receiving raltegravir-containing ART

Clarke D, Acosta E, Chain A, Cababasay M, Wang J, Teppler H, Smith E, Hazra R, Popson S, Graham B, Calabrese K, Bryson Y, Spector S, Mirochnick M

Poster presentation,
12:45 – 14:00;

Poster discussion,
17:00 – 17:30

P1101

Phase I/II study of raltegravir-containing regimen in HIV and TB co-treated children aged 6-<12 years

Krogstad P, Samson P, Meyers T, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Hovind L, Sise T, Teppler H, Dittmer S, Fairlie L, Hesseling AC, Cotton MF

Poster presentation

P1093

Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093

Ruel T, Acosta EP, Singh R, Alvero C, Fenton T, George K, Townley E, Hazra R, Popson S, Buchanan AM, Brothers C, Vavro C, Wiznia A, and the IMPAACT P1093 Team

Oral presentation

P1093

Emergence of resistance in HIV-1 Integrase following dolutegravir (DTG) treatment in 6 to <18 year old participants enrolled in the P1093 study

Vavro C, Ruel T, Wiznia A, Alvero C, Popson S, Fenton T, Hazra R, Townley E, Buchanan A, and Palumbo P

Poster

P1093

Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to < 6 years: Results from IMPAACT P1093

Ruel T, Acosta E, Singh R, Alvero C, Fenton T, George K, Popson S, Townley E, Hazra R, Brothers C, Vavro C, Buchanan A, Wiznia A, IMPAACT P1093 Team

Poster presentation, Hall 1,
12:30 – 14:30 (LBPEB023)

P1104s

Caregiver depression and child neuropsychological outcomes in an observational study carried out in four Sub-Saharan countries

Familiar I, Chernoff M, Ruisenor-Escudero H, Laughton B, Joyce C, Fairlie L, Bwakura-Dangarembizi M, Kamthunzi P, Barlow L, Jean-Philippe P, Zimmer B, McCarthy K, Boivin M

Poster presentation, Hall 1,
12:30 – 14:30 (TUPEC222)

P1026s

Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum

Momper JD, Best B, Wang J, Stek A, Shapiro DE, George K, Barr E, Rungruengthanakit K, Smith E, Chakhtoura N, Capparelli EV, Mirochnick M

Poster presentation, Hall 1,
12:30 – 14:30 (WEPEB118)

P1074/ CIPHER

Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a CIPHER cohort collaboration global analysis

Patel K, Smith C, Collins IJ, Goodall R, Abrams E, Sohn A, Mohamed T, Van Dyke R, Rojo P, Wools-Kaloustian K, Pinto J, Edmonds A, Marete I, Paul M, Nuwaqaba-Biribonwoha H, Leroy V, Davies M-A, Vreeman R, CIPHER Cohort Collaboration Duration of Second-line Proj

Oral abstract,
Hall 10, 14:30 – 16:00
(WEAB0203)

PROMISE

Developmental and cognitive effects of type of antepartum and postpartum ARV exposure for Ugandan and Malawian IMPAACT PROMISE HIV-exposed versus unexposed children at age 12, 24 and 48 months

Boivin M, Maliwichi-Senganimalunje L, Wambuzi Ogwang L, Kawalazira R, Sikorskii A, Familiar-Lopez I, Kuteesa A, Nyakato M, Mutebe A, Makitende M, Mallewa M, Ruisenor-Escudero H, Aizire J, Taha T, Fowler MG

Oral presentation, Hall 10,
14:30 – 14:45 (WEAB0201) and poster

P1093

Emergence of resistance in HIV-1 integrase (IN) following dolutegravir (DTG) treatment in 6 to 18 year old participants enrolled in the P1093 study

Vavro C, Ruel T, Wiznia A, Alvero C, Popson S, Fenton T, Hazra R, Townley E, Buchanan A, Palumbo P

Poster presentation, Hall 1,
12:30 – 14:30 (THPEB114)

PROMISE 1077BF

Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component

Flynn P, Taha T, Cababasay M, Butler K, Fowler MG, Mofenson L, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanshanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga B, Masenya M, Nyati M, Theron G, Mulenga H, Shapiro D, and the PROMISE Study Team

Poster presentation, Hall 1,
12:30 – 14:30 (THPEB115)

P1026s

Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy

Momper JD, Best B, Wang J, Stek A, Cressey TR, Burchett S, Kreitchmann R, Shapiro DE, Smith E, Chakhtoura N, Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol Team

Oral presentation, Hall 11a,
16:45 – 17:00 (THAB0302)